Journal: Translational Neurodegeneration
Article Title: Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease
doi: 10.1186/s40035-025-00503-7
Figure Lengend Snippet: Therapeutic effects of PPR@siBACE1 in AD transgenic mice. a qRT-PCR analysis of BACE1 mRNA expression in the hippocampus and cortex of AD mice treated with different formulations, and WT mice treated with PBS. b and c Representative western blots for BACE1 and MBP proteins in the hippocampus and cortex of AD mice treated with different formulations, and WT mice treated with PBS. d Immunofluorescence detection of Aβ plaques (yellow) in the hippocampus and cortex of AD and WT mice, with nuclei stained with DAPI (blue). Scale bars, 100 μm. e ELISA analysis of Aβ 1-42 levels in the brains of mice from different groups. g Immunofluorescent staining of microglia with anti-Iba1 (green) in the hippocampus. Scale bars: 100 μm (original figure), 5 μm (magnified inset). h Immunofluorescent staining of astrocytes using anti-GFAP (red) in the hippocampus. Scale bars: 100 μm (original figure), 5 μm (magnified inset). f , i , j qRT-PCR analysis of the mRNA expression of inflammatory cytokines TNF-α ( f ), IL-1β ( i ), and IL-6 ( j ) in the brains of mice. k ELISA analysis of Aβ 1-42 levels in circulating exosomes in the blood of mice. Mean ± SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 vs the AD-PBS group
Article Snippet: Antibodies used in this study included: primary antibodies for Aβ (803014, Biolegends, San Diego, CA), glial fibrillary acidic protein (GFAP) (AB53554, Abcam, Cambridge, UK), Iba1 (019-19741, Wako, Osaka, Japan), Nissl ( N21482 , Thermo Fisher Scientific, Waltham, MA), myelin basic protein (MBP) (MCA409S, BioRad, Hercules, CA), BACE1 ( AB183612 , Abcam), β-actin (AB8226, Abcam).
Techniques: Transgenic Assay, Quantitative RT-PCR, Expressing, Western Blot, Immunofluorescence, Staining, Enzyme-linked Immunosorbent Assay